系统性红斑狼疮靶向治疗进展

Advances in Targeted Therapy of Systemic Lupus Erythematosus

系统性红斑狼疮(SLE)是一种病因及发病机制至今尚不明确的自身免疫性疾病。其发病人数逐年增加,而传统治疗方法疗效有限。近年来系统性红斑狼疮靶向治疗的研究提供了更多的方法及策略,如B细胞靶向治疗、细胞因子靶向治疗、阻断联合刺激信号、T细胞靶向治疗等。其中以B细胞靶向治疗最为成熟,贝利木单抗为最好的例子,针对B细胞刺激细胞因子(BLyS)进行阻断,目前已通过美国食品和药物管理向批准用于SLE的治疗。本文参考国内外文献综述分析了新的治疗方法——靶向治疗的进展,特别着重于药物的临床试验。

The causes and mechanisms of systemic lupus erythematosus（SLE） are still not clear. The morbidity increases rapidly, but traditional treatment efficacy is not satisfactory. Recent insights into targeted therapy provide new selective therapies of SLE, such as B cell targeted strategies, cytokine directed therapy, costimulation blockage, and T cell targeted strategies. The best exam- ple is Belimumab, which targets the B cell cytokine BLyS and has now received Food and Drug Administration （FDA） approval for its use in SLE. This paper reviewed the targeted therapy for SLE, with particular focus on new drug clinical trials.